Abstract
Purpose. To investigate the cellular proteolytic activities of various lung pneumocytes using luteinizing hormone releasing hormone (LHRH) and [D-Ala6]-LHRH as model peptide substrates.
Methods. HPLC analysis was used to investigate the degradation kinetics of LHRH/[D-Ala6]-LHRH and to identify their degradation products in isolated lung pneumocytes.
Results. Pulmonary macrophages exhibited the strongest proteolytic activity against LHRH)/[D-Ala6]-LHRH. followed by type II and type I-like pneumocytes. Three major degradation products of LHRH, namely LHRH 4−10, LHRH 6−10, and LHRH 7−10, were identified in macrophages and type II pneumocytes, whereas in type I-like pneumocytes only the LHRH 7−10 was found. Co-incubation of the cells with known enzyme inhibitors including captopril (an ACE inhibitor), thiorphan (an EP24.11 inhibitor), and EDTA (an EP24.15 inhibitor) inhibited the formation of LHRH 4−10, LHRH 7−10, and LHRH 6−10 respectively. In all cell types, the degradation rate of [D-Ala6]-LHRH was about 3−8 times lower than that of LHRH. This peptide analog was resistant to degradation by EP24.15 and EP24.11. but was susceptible to ACE.
Conclusions. ACE, EP24.11, and EP24.15 are the major enzymes responsible for the degradation of LHRH in macrophages and type II pneumocytes. The magnitude of peptidase activities in these cell types are: EP24.15 > EP24.11 ≈ ACE. No EP24.15 or ACE activity was observed in type I-like pneumocytes and only a weak EP24.11 activity was detected.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
J. S. Patton and R. M. Platz. Routes of delivery: Case study. Pulmonary delivery of peptides and proteins for systemic action. Adv. Drug Deliv. Rev. 8:179–196 (1992).
K. C. Stone, R. R. Mercer, P. Gehi, and J. D. Crapo. Allometic relationships of cell numbers and size in the mammalian lung. Am. Respir. Cell Mol. Biol. 6:235–243 (1992).
I. Y. Adamson and D. H. Bowden. Dose response of the pulmonary macrophagic system to various particles and its relationship to transepithelial passage of free particles. Exp. Lung Res. 2:165–175 (1981).
I. Y. Adamson and D. H. Bowden. The type II cell as progenitor of alveolar epithelial regeneration: A cytodynamic study in mice after exposure to oxygen. Lab. Invest. 30:35–42 (1974).
L. Y. Wang, D. Toledo, D. B. Schwegler, J. K. H. Ma, and Y. Rojanaskul. Transport and hydrolysis of enkephalins in cultured alveolar epithellial monolayers. Pharm. Res. 10:1662–1667 (1993).
J. M. Cheek, M. J. Evans, and E. D. Crandall. Type I cell-like morphology in tight alveolar epithelial monolyers. Exp. Cell Res. 184: 375–387 (1989).
S. I. Danto, S. M. Zabski, and E. D. Crandall. Reactivity of alveolar epithelial cells in primary culture with type I cell monoclonal antibodies. Am. J. Respir. Cell Mol. Biol. 6:296–306 (1992).
R. J. van Klaveren, C. Roelant, M. Boogaerts, M. Demedts, and B. Nemery. Involvement of an NAD(P)H oxidase-like enzyme in superoxide anion and hydrogen peroxide generation by rat type II cells. Thorax 52:465–471 (1977).
S. M. MacCann. Luteinizing-hormone-releasing-hormone. Physiol. Med. 296:797–802 (1977).
M. Orlowski, C. Michaud, and T. G. Chu. A soluble metalloendopeptidase from rat brain. Purification of the enzyme and determination of specificity with synthetic and natural peptides. Eur. J. Biochem. 135:81–88 (1983).
K. Han, J. S. Park, Y. B. Chung, M. J. Lee, D. C. Moon, and J. R. Robinson. Identification of enzymatic degradation products of luteinizing hormone releasing hormone (LHRH)/[D-Ala6] LHRH in rabbit mucosal homogenates. Pharm. Res. 12:1539–1544 (1995).
R. A. Skidgel and E. G. Erdos. Hydrolysis of substance P and neurotensin by converting enzyme and neutral endopeptidase. Peptides 5:769–776 (1984).
C. J. Molineaux, A. L. Lasdun, and M. Orlowski. Endopeptidase 24.15 is the primary enzyme that degrades luteinizing hormone releasing hormone both in vitro and in vivo. J. Neurochem. 51:624–633 (1988).
E. G. Erdos. Multiple functions of human converting enzyme and enkephalinase in peptide metabolism. Jp. J. Hypertension 6:71–80 (1984).
J. R. Edelson, J. M. Shannon, and R. J. Mason. Alkaline phosphatase: a marker of alveolar type II cell differentiation. Am. Rev. Respir. Dis. 138:1268–1275 (1988).
S. D. Kashi and V. H. L. Lee. Enkephalin hydrolysis in homogenates of various absorptive mucosae of the albino rabbit: Similarities in rates and involvement of aminopeptidases. Life Sci. 38:2019–2028 (1986).
A. Adjei and J. Garren. Pulmonary delivery of peptide drugs: Effect of particle size on bioavailability of leuprolide acetate in healthy male volunteers. Pharm. Res. 7:565–569 (1990).
A. J. Turner, R. Matsas, and A. J. Kenny. Are there neuropeptide-specific peptidases? Biochem. Pharmacol. 34:1347–1356 (1985).
R. Maggi, D. Dondi, P. Limonta, F. Pimpinelli, M. Montagnani, R. M. Moretti, M. Motta. Characterization of a soluble LHRH-degradation activity in the rat ventral prostate. Prostate 23:315–328 (1993).
G. Flouret, T. Majewski, D. R. Peterson, and A. J. Kenny. Effect of D-amino acid substituents on degradation of LHRH analogues by proximal tubule. Am. Physiol. E320–D326 (1987).
T. Nakamura, T. Nagata, Y. Tanabe, N. Yanaihara, and Y. Hasegawa. Comparison of in vivo biological activities of luteinizing hormone-releasing hormone (LHRH) analogues in 60-day old cockerels. Gen. Comp. Endocrinol. 83:290–296 (1991).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yang, X., Rojanasakul, Y., Wang, L. et al. Enzymatic Degradation of Luteinizing Hormone Releasing Hormone (LHRH)/[D-Ala6]-LHRH in Lung Pneumocytes. Pharm Res 15, 1480–1484 (1998). https://doi.org/10.1023/A:1011926310666
Issue Date:
DOI: https://doi.org/10.1023/A:1011926310666